246 related articles for article (PubMed ID: 18819960)
1. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Pocock SJ; McMurray JJ; Dobson J; Yusuf S; Granger CB; Michelson EL; Ostergren J; Pfeffer MA; Solomon SD; Anker SD; Swedberg KB
Eur Heart J; 2008 Nov; 29(21):2641-50. PubMed ID: 18819960
[TBL] [Abstract][Full Text] [Related]
2. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
[TBL] [Abstract][Full Text] [Related]
3. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
5. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Kenchaiah S; Pocock SJ; Wang D; Finn PV; Zornoff LA; Skali H; Pfeffer MA; Yusuf S; Swedberg K; Michelson EL; Granger CB; McMurray JJ; Solomon SD;
Circulation; 2007 Aug; 116(6):627-36. PubMed ID: 17638930
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
8. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
[TBL] [Abstract][Full Text] [Related]
9. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
[TBL] [Abstract][Full Text] [Related]
10. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
[TBL] [Abstract][Full Text] [Related]
12. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
[TBL] [Abstract][Full Text] [Related]
13. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
[TBL] [Abstract][Full Text] [Related]
14. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Pocock S; Wang D; Wilhelmsen L; Hennekens CH
Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Piña IL; Granger CB; Ostergren J; Michelson EL; Solomon SD; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
Circulation; 2007 Jun; 115(24):3111-20. PubMed ID: 17562950
[TBL] [Abstract][Full Text] [Related]
16. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
Solomon SD; Anavekar N; Skali H; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Wang D; Pocock S; Pfeffer MA;
Circulation; 2005 Dec; 112(24):3738-44. PubMed ID: 16330684
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
18. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E; Lewis E; Granger C; Dunlap ME; McKelvie RS; Probstfield JL; Young JB; Michelson EL; Ostergren J; Carlsson J; Olofsson B; McMurray J; Yusuf S; Swedberg K; Pfeffer MA
Eur J Heart Fail; 2005 Jun; 7(4):650-6. PubMed ID: 15921807
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
20. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Solomon SD; Wang D; Finn P; Skali H; Zornoff L; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pocock S; Pfeffer MA
Circulation; 2004 Oct; 110(15):2180-3. PubMed ID: 15466644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
